MedTrace Logo

Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis

NCT00456092 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2020-06-19

Study results available
· View outcomes & findings →

Summary

This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.

Conditions

Interventions

DRUG

Apremilast

Capsules for oral administration

DRUG

Placebo

Capsules for oral administration

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-05
Primary Completion
2009-05-09
Completion
2009-05-09

Countries

  • Belgium
  • Canada
  • Germany
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00456092 on ClinicalTrials.gov